In this study, we discovered that, under oxaliplatin treatment, CRC cells phosphorylate RFNG at the Ser255 residue through the MAPK kinase ERK, leading to the binding of RFNG to nuclear importin proteins and its subsequent entry into the nucleus. This evidence concerns the gene RFNG and colorectal carcinoma.